A Non-interventional, Post-authorization Safety Study of Patients with Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden (CC-5013-MCL-005)

02/05/2018
19/01/2026
EU PAS number:
EUPAS23366
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

cc-5013-mcl-005-protamend5-0_redacted.pdf

English (4.28 MB - PDF) View document
Study results
Study report
Study report

CC-5013-MCL-005 Final Study Report_Redacted

English (12.94 MB - PDF) View document
Other information
Study, other information

CC-5013-MCL-005_Site List_10Jun2020

English (70.45 KB - PDF) View document

CC-5013-MCL-005_Site List_2022-05-16

English (96.49 KB - PDF) View document